Boston Scientific and Acotec Scientific announced that Boston Scientific will make a partial offer to acquire a majority stake, up to a maximum of 65%, of shares of Acotec, a Chinese medical technology company that offers solutions designed for a variety of interventional procedures. The proposed price is HK$20 per share, which represents a total upfront cash payment consideration of approximately $523 million for the 65% stake at current exchange rates. Boston Scientific expects the impact to adjusted earnings per share to be immaterial in 2023 and the impact to GAAP earnings per share to be less accretive, or dilutive, as the case may be, due to amortization expense and acquisition-related net charges. The completion of the transaction, which is anticipated in the first half of 2023, is subject to acceptance and approval by Acotec shareholders and other conditions set forth in related filings.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BSX:
- Boston Scientific Snaps up a Stake in Acotec
- Boston Scientific Announces Strategic Investment to Acquire Majority Stake of Acotec Scientific Holdings Limited
- Boston Scientific price target raised to $54 from $48 at Raymond James
- Wolfe Research cuts Edwards Lifesciences to Peer Perform on macro, TAVR maturity
- Apollo Endosurgery downgraded to Hold from Buy at Lake Street